Aptinyx Inc.

Good afternoon and welcome to the Aptinex Third Quarter 2021 Financial Results Conference Call. At this time, all participants are on listen-only mode. Following the formal remarks, we will open the call for your questions. Please be advised that the call is being recorded at the company's request. At this time, I would like to turn the call over to Patrick Flavin, Senior Manager, Corporate Development and Investor Relations at Aptinex. Patrick, please proceed.

Good afternoon, everyone, and thanks for joining us on today's conference call to discuss Apptinex's financial and operating results for the third quarter of 2021. Our press release describing financial results and recent highlights is now available on our website. Today on our call, Norbert Riedel, our chief executive officer, will review recent business updates. Then Andy Kidd, our president and chief operating officer, will review progress across our development programs, followed by Ashish Khanna, our chief financial officer and chief business officer, who will review the financial results. In addition, Katherine King, Senior Vice President of Clinical and CMC Operations, and Harold Merck, Vice President of Clinical and Medical Affairs, are on the line for the Q&A portion of the call. Before we begin, I would like to remind everyone the statements made during this conference call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties that can cause actual results to differ materially. Any forward-looking statements are made only as of today, and we disclaim any obligation to update these forward-looking statements. Please see the forward-looking statement disclaimer in our financial results release issued this afternoon and the risk factors in the company's current and subsequent filings with the SEC. I'm now happy to turn the call over to Norbert to kick things off.

Thank you, Pat, and good afternoon, everyone. We appreciate you taking the time to join us on today's call. Before we begin with updates from our clinical program, I would like to extend a warm welcome to Dr. Gilmore O'Neill, our newest colleague on the Aptinix Board of Directors. Dr. O'Neill has extensive experience in CNS drug development, academic medicine, and as a practicing neurologist. He currently serves as Executive Vice President of R&D and Chief Medical Officer at Sarepta Therapeutics, where he leads the company's research, clinical development, medical affairs, pharmacovigilance, and regulatory affairs functions. He also brings an impressive background in late-stage CNS drug development from his previous 15-year tenure at Biogen, where he held leadership roles across numerous programs in neurology, pain, gene and cell therapy, and rare diseases, including oversight of numerous global marketing approvals. I am confident Gilmore will serve as an invaluable resource in helping to guide our future development and growth plans, and we are thrilled to welcome him aboard. These past several months have been a particularly productive time for Aptinix, and we are looking forward to an active period of execution and multiple data catalysts ahead. Later this year, we plan to initiate our Phase IIb development program of NYX783 in patients with PTSD. We also recently announced that we expect to report results from our Phase IIb study of NYX2925 in painful diabetic peripheral neuropathy in the second quarter of 2022. Meanwhile, Enrollment in our studies of NYX2925 in fibromyalgia and NYX458 in cognitive impairment is progressing well, with readouts anticipated in mid-2022 and the second half of 2022, respectively. With this slate of clinical development programs moving full speed ahead, we are very pleased to have a strong balance sheet bolstered by a gross credit facility with secured during the last quarter, providing access to up to $50 million. Our current capital position is expected to fund phase two data readouts from each of our pipeline programs across 2022 and 2023. Recall that during our last quarterly call, we announced our plans for the shift transition. in which Andy Kidd will become president and CEO, and I will assume the role of executive chairman effective January 1st, 2022. The rollout of that transition has continued to proceed very well, and our team is prepared to hit the ground running in the new year. I will now turn the call over to Andy to dive into more detail about each of our programs beginning with NYX2925 and chronic pain.